D.A. Davidson & CO. lifted its holdings in Shire PLC (NASDAQ:SHPG) by 16.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,471 shares of the biopharmaceutical company’s stock after purchasing an additional 2,330 shares during the quarter. D.A. Davidson & CO.’s holdings in Shire PLC were worth $2,522,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of SHPG. Janus Henderson Group PLC increased its position in Shire PLC by 22,560.3% during the second quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock valued at $212,683,000 after acquiring an additional 1,281,202 shares during the last quarter. Glenview Capital Management LLC increased its position in Shire PLC by 69.7% during the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after acquiring an additional 707,500 shares during the last quarter. Northern Trust Corp increased its position in Shire PLC by 45.5% during the second quarter. Northern Trust Corp now owns 1,307,339 shares of the biopharmaceutical company’s stock valued at $216,064,000 after acquiring an additional 408,843 shares during the last quarter. OZ Management LP purchased a new stake in Shire PLC during the second quarter valued at $57,614,000. Finally, Maverick Capital Ltd. increased its position in Shire PLC by 19.9% during the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock valued at $320,969,000 after acquiring an additional 322,610 shares during the last quarter. Hedge funds and other institutional investors own 18.64% of the company’s stock.

A number of analysts recently commented on the company. Barclays PLC cut Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Jefferies Group LLC reiterated a “hold” rating and set a $206.00 price objective (down previously from $216.00) on shares of Shire PLC in a research report on Wednesday, August 9th. Liberum Capital upgraded Shire PLC from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Royal Bank Of Canada reiterated a “buy” rating and set a $213.00 price objective on shares of Shire PLC in a research report on Monday, October 2nd. Finally, Cantor Fitzgerald set a $222.00 price objective on Shire PLC and gave the company a “buy” rating in a research report on Thursday, November 16th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Shire PLC currently has a consensus rating of “Buy” and a consensus target price of $212.18.

Shares of Shire PLC (NASDAQ SHPG) opened at $147.86 on Friday. Shire PLC has a fifty-two week low of $137.17 and a fifty-two week high of $192.15. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $44,997.96, a PE ratio of 10.30, a price-to-earnings-growth ratio of 0.83 and a beta of 1.60.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The business had revenue of $3.70 billion during the quarter. During the same period in the prior year, the firm posted $3.17 EPS. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. equities research analysts expect that Shire PLC will post 15 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Shire PLC (SHPG) Stake Lifted by D.A. Davidson & CO.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/25/shire-plc-shpg-stake-lifted-by-d-a-davidson-co.html.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.